Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.

ABSTRACT:

Background

Human epidermal growth factor receptor 2 (HER2) has emerged as an important prognostic and therapeutic target in advanced stage and recurrent uterine serous carcinoma (USC). The significance of tumoral HER2 expression in early-stage disease has not been established.

Methods

This multi-center cohort study included women with stage I USC treated from 2000 to 2019. Demographic, treatment, recurrence, and survival data were collected. Immunohistochemistry (IHC) was performed for HER2 and scored 0-3+. Equivocal IHC results (2+) were further tested with fluorescence in-situ hybridization (FISH). HER2 positivity was defined as 3+ IHC or FISH positive.

Results

One hundred sixty-nine patients with stage I USC were tested for HER2; 26% were HER2-positive. There were

SUBMITTER: Erickson BK 

PROVIDER: S-EPMC7541557 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature